TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
A user with aggressive male pattern baldness found that topical melatonin significantly reduced their hair shedding to 1 or 2 hairs per day and noticed some thickening of side hair. They tried many treatments like finasteride and minoxidil with little success, but topical melatonin showed immediate results in reducing hair loss.
The conversation discusses the lack of significant advancements in hair loss treatments since the introduction of finasteride 22 years ago, with many expressing frustration over the failure of new projects and skepticism about future developments. Some users mention hair transplants and other potential alternatives like Alfatradiol and Fluridil, but acknowledge finasteride's dominance in the market due to its effectiveness and affordability.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
User questions credibility of a hair loss "cure" found by a non-expert and warns against wasting money on unproven supplements. Others discuss trying natural extracts and the importance of researching the enzyme 3ADH for potential hair growth benefits.
Redensyl, a hair loss treatment that has been claimed to be 80% more effective than minoxidil, but users have not experienced any results from using it.
Regrowing hairline without the use of Minoxidil or Finasteride, and instead using mechanical stimulation such as Derma Roller, Nizoral, Zinc Pyrithione, Scalp Massage, Scalp Exercise, Fish Oil and other topical solutions. It is cautioned that there are risks associated with not using medically-prescribed treatments, but it is suggested to consider mechanical stimulation in addition to those prescribed treatments.
Hair loss treatments, including minoxidil, dermarolling, finasteride, dutasteride, hair transplants, hair systems, and shaving the head. The conversation covers various opinions on these treatments and mentions possible side effects as well as alternatives like wigs, vitamins, and lifestyle changes. The post expresses disappointment that there has been no major breakthrough in the field of hair loss treatments despite decades of research.
Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.
Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.
The conversation discusses the progress and potential of hair cloning by Stemson Therapeutics, questioning if it will be realized in the next 5-10 years or if it's just false hope. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It highlights an interview with Stemson Therapeutics CEO Geoff Hamilton about advancements in hair cloning technology.
Hair cloning trials by Stempsen Therapeutics and Hairclone have no updates, and it may take at least 15 years for hair cloning to be available. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.
CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.
Exploring future hair loss treatments, including immunosuppressants for hair transplants and hair cloning, with a focus on leveraging research from other medical fields. Current treatments like finasteride and minoxidil are effective for most, but there's a call for more funding and innovation in the hair loss industry.
Hair follicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.
Dutasteride and finasteride have similar risk profiles despite Dutasteride blocking more types of 5AR in the brain. Some users report no mood issues with either drug, and it is suggested that Dutasteride's larger molecular size may limit its ability to cross the blood-brain barrier.
Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Gene editing to reactivate dormant follicles is suggested as a more likely solution within the next ten years.
The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
A new study that found a single chemical could potentially be responsible for hair loss, and the potential to use this discovery to stimulate hair growth. The conversation also includes various treatments such as Minoxidil, Finasteride, RU58841, microneedling, DUT, and Botox for hair loss.
Hair cloning is discussed, focusing on its current status and potential availability. Treatments mentioned include Minoxidil, finasteride, and RU58841.
L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.